The development of targeted therapy in small cell lung cancer

被引：26

作者：

Zhang, Yalei ^{[1
]}

He, Jianxing ^{[1
]}

机构：

[1] Guangzhou Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Guangzhou 510120, Peoples R China

来源：

JOURNAL OF THORACIC DISEASE | 2013年 / 5卷 / 04期

关键词：

Small cell lung cancer (SCLC); angiogenesis inhibitors; cell signalling inhibitors; apoptosis promoters; multidrug resistance inhibitors; PHASE-II TRIAL; GROWTH-FACTOR RECEPTOR; PACLITAXEL PLUS BEVACIZUMAB; DOUBLE-BLIND; INDUCTION CHEMOTHERAPY; BCL-2; PROTEIN; FACTOR VEGF; INHIBITOR; IRINOTECAN; IMATINIB;

D O I：

10.3978/j.issn.2072-1439.2013.07.04

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Small cell lung cancer (SCLC) is a highly aggressive cancer usually with distal metastasis and very poor prognosis. Chemotherapy is the treatment of choice for SCLC in all stages and an initial good response, but there is a high chance of disease relapse with an overall poor median survival for both stages. With increasing translational research and a better understanding of the molecular basis of cancer, a number of molecular targets have been identified in various preclinical studies. Targeted drugs have less toxicity than chemotherapy drugs, but no targeted agents have been approved for use in the treatment of SCLC patients to date. This review focuses on targeted therapies in SCLC.

引用

页码：538 / 548

页数：11

共 68 条

[1]

[Anonymous], 13 WORLD C LUNG CANC

[2] Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer [J].

Antonia, SJ ;

Mirza, N ;

Fricke, I ;

Chiappori, A ;

Thompson, P ;

Williams, N ;

Bepler, G ;

Simon, G ;

Janssen, W ;

Lee, JH ;

Menander, K ;

Chada, S ;

Gabrilovich, DI .

CLINICAL CANCER RESEARCH, 2006, 12 (03) :878-887

[3]

Arnold AM, 2007, J CLIN ONCOL, V25, P4278, DOI 10.1200/JCO.2007.12.3083

[4]

Besse B, 2009, 13 WORLD C LUNG CANC

[5] A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study [J].

Dy, GK ;

Miller, AA ;

Mandrekar, SJ ;

Aubry, MC ;

Langdon, RM ;

Morton, RF ;

Schild, SE ;

Jett, JR ;

Adjei, AA .

ANNALS OF ONCOLOGY, 2005, 16 (11) :1811-1816

[6]

Gandhi L, 2009, J CLIN ONCOL, V27

[7] A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer [J].

Gandhi, Leena ;

Harding, Matthew W. ;

Neubauer, Marcus ;

Langer, Corey J. ;

Moore, Melvin ;

Ross, Helen J. ;

Johnson, Bruce E. ;

Lynch, Thomas J. .

CANCER, 2007, 109 (05) :924-932

[8] Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors [J].

Gandhi, Leena ;

Camidge, D. Ross ;

de Oliveira, Moacyr Ribeiro ;

Bonomi, Philip ;

Gandara, David ;

Khaira, Divis ;

Hann, Christine L. ;

McKeegan, Evelyn M. ;

Litvinovich, Elizabeth ;

Hemken, Philip M. ;

Dive, Caroline ;

Enschede, Sari H. ;

Nolan, Cathy ;

Chiu, Yi-Lin ;

Busman, Todd ;

Xiong, Hao ;

Krivoshik, Andrew P. ;

Humerickhouse, Rod ;

Shapiro, Geoffrey I. ;

Rudin, Charles M. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07) :909-916

[9] Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-0897113; Silva Study) [J].

Giaccone, G ;

Debruyne, C ;

Felip, E ;

Chapman, PB ;

Grant, SC ;

Millward, M ;

Thiberville, L ;

D'addario, G ;

Coens, C ;

Rome, LS ;

Zatloukal, P ;

Masso, O ;

Legrand, C .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :6854-6864

[10] Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer A Southwest Oncology Group (SWOG 0435) Phase II Trial [J].

Gitlitz, Barbara J. ;

Moon, James ;

Glisson, Bonnie S. ;

Reimers, H. Joachim ;

Bury, Martin J. ;

Floyd, Justin D. ;

Schulz, Thomas K. ;

Sundaram, P. Kothai ;

Ho, Christopher ;

Gandara, David R. .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (11) :1835-1840

← 1 2 3 4 5 6 7 →